share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Mar 23 04:03
Summary by Futu AI
CRISPR Therapeutics officer Phuong Khanh Morrow is set to sell 50,767 shares of the company's common stock on 03/22/2024, as per the latest filings. The shares, valued at approximately $3,699,269.45, were acquired on the same date through the exercise of stock options. The transaction involved a cash payment to the issuer for the securities. This sale comes without any reported transactions by Morrow in the past three months.
CRISPR Therapeutics officer Phuong Khanh Morrow is set to sell 50,767 shares of the company's common stock on 03/22/2024, as per the latest filings. The shares, valued at approximately $3,699,269.45, were acquired on the same date through the exercise of stock options. The transaction involved a cash payment to the issuer for the securities. This sale comes without any reported transactions by Morrow in the past three months.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.